United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

19 Jan 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Mesoblast Ltd's key patent allowed in Japan for treatment of heart diseases, stroke, and other vascular conditions
Thursday, 26 Mar 2015 06:45pm EDT 

Mesoblast Ltd:Announced that Japanese Patent Office has allowed key patent covering use of the company's proprietary adult Mesenchymal Precursor Cells (MPCs) for formation and repair of blood vessels in ischemic tissues.Japanese patent 2006-503990, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, covers use of these cells derived from bone marrow, adipose tissue and dental pulp.Says that this patent provides commercial rights in Japan through to at least March 29, 2024, with potential for patent term extension for up to five years based on duration of clinical development.  Full Article

BRIEF-Mesoblast qtrly loss per share 5.24 cents

* Mesoblast provides corporate update and financial results for the first quarter ended September 30, 2016 Source text for Eikon: Further company coverage: